IPAR Sales Grow 26% On 'Premiumization' Streak, As Symrise Earnings Stumble Over Production Issues: Briefs

New York-based Inter Parfums, Inc. says continued “premiumization’ trends in fragrance helped drive its sales up 26% in the second quarter, while German company Symrise AG’s two recent purchases in the fragrance space added €15m to sales in the first-half of the year. Separately, Revlon announces interim CEO as head Debra Perelman steps down.

Inter Parfums, Inc. reports sales increased 26% for the three-months ended 30 June to $309m, as the New York-based firm takes advantage of positive trends and momentum in the fragrance market, while growing its market share with innovative programs, Chairman and CEO Jean Madar says in an 8 August earnings release. “Through the first half of the year, our robust growth has been geographically spread across our 120-country distribution footprint and included signs of renewed life in the travel retail business,” he said, adding the firm is taking a conservative approach to China, which should experience modest sales growth for the remainder of the year. During a first quarter earnings presentation in May, during which the company reported 24% growth, Madar noted a “premiumization” of products across the US, Europe and Asia, with consumers buying more expensive, larger and more concentrated formulas. (Also see "Inter Parfums Expects ‘Another Spectacular Year’ As Prestige Fragrance Boom Continues" - HBW Insight, 10 May, 2023.)

Net income for the quarter grew 27% to $35m. Looking ahead, Madar noted the company is “strategizing and building out”...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Europe

EU JCA: Milestone Report Shows Room For Improvement For Orphan Drugs And PICOs

In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

Marinomed Starts Restructuring Proceedings As Debts Mount

 
• By 

Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.

Perrigo Adds High-Strength Paracetamol To UK Solpadeine Line

 
• By 

Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative. 

More from Geography

Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

 

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By 

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.